Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 7/20 | 0.65 |
| ▸ | CDK2 | P24941 | 7/20 | 0.65 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.65 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791972 | 0.89 | ALDH1A1 (0.53) | CCNA2CDK2CCNA1RAD52ALDH1A1 | |
| SCHEMBL6793988 | 0.86 | CCNA2 (0.62) | CCNA2CDK2CCNA1RAD52F2 | |
| SCHEMBL5371941 | 0.86 | CA9 (0.50) | CCNA2CDK2CCNA1RAD52ALDH1A1 | |
| SCHEMBL12046675 | 0.83 | CCNA2 (0.55) | CCNA2CDK2CCNA1RAD52SMN1; SMN2 | |
| SCHEMBL6793613 | 0.82 | CCNA2 (0.52) | CCNA2CDK2CCNA1RAD52SMN1; SMN2 | |
| SCHEMBL11871559 | 0.81 | RAD52 (0.62) | CCNA2CDK2CCNA1RAD52ALDH1A1 | |
| SCHEMBL19128204 | 0.81 | CCNA2 (0.54) | CCNA2CDK2CCNA1RAD52SMN1; SMN2 | |
| SCHEMBL11858649 | 0.80 | RAD52 (0.69) | CCNA2CDK2CCNA1RAD52SMN1; SMN2 | |
| SCHEMBL12046664 | 0.80 | RAD52 (0.51) | CCNA2CDK2CCNA1RAD52SMN1; SMN2 | |
| SCHEMBL11867763 | 0.79 | RAD52 (0.70) | CCNA2CDK2CCNA1RAD52SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CCNA2 270/4885CDK2 29/4885CCNA1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.